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Key messages
What is already known about this subject?
 ► Systemic sclerosis (SSc) is a severe, progressive 
multiorgan disease but to date, there are no estab-
lished standardised international guidelines for fol-
low-up of patients with SSc.
What does this study add?
 ► through this study, a consensus on strongly sug-
gested and easily applicable tools for a minimum 
annual systemic assessment of organ involvement 
in SSc was established with world leading experts.
How might this impact on clinical practice?
 ► the development of these easily applicable tools 
may ensure an adequate standard of care for all pa-
tients with SSc and enhance the standardisation and 
homogenisation of the practices worldwide.
AbstrAct
Background Systemic sclerosis (SSc) is a severe, 
progressive multiorgan disease but to date, there are 
no established standardised international guidelines for 
follow-up of patients with SSc. the goal of this project 
was to develop an expert consensus for annual systematic 
investigations in patients with SSc to enhance their 
standard-of-care.
Material and methods the Delphi method was applied. 
all SSc experts from the european Scleroderma trials and 
research group network and the Scleroderma clinical 
trial consortium were invited to participate. all experts 
were asked to answer questionnaires in five Delphi steps 
to determine the domains of interest and tools for each 
domain for an annual systematic assessment of patients 
with SSc. each item was rated on a scale between 0% 
and 100% (not and very important), and parameters rated 
>80% by more than 75% of the experts were regarded as 
acceptable.
Results in total, 157 experts worldwide participated with 
71.3% experts seeing >50 patients with SSc annually. in 
the first round, 23 domains and 204 tools were suggested. 
after five Delphi steps, experts agreed on 10 domains 
including (1) raynaud’s phenomenon; (2) Digital ulcers; 
(3) Skin and mucosa; (4) lung; (5); Heart; (6) gi domain, 
(7) renal; (8) Musculoskeletal; (9) laboratory and (10) 
treatment. Overall, 55 tools were identified including 
clinical assessments, laboratory measurements and 
imaging or functional investigations.
Conclusion through five Delphi steps with world 
leading experts, a consensus was established on 
strongly suggested tools for a minimum annual systemic 
assessment of organ involvement in SSc. this work should 
enhance the standardisation and homogenisation of the 
practices.
InTRoduCTIon
Systemic sclerosis (SSc) is a severe multio-
rgan disease that is associated with substantial 
morbidity and mortality and impaired quality 
of life.1–5 Lung and heart involvement are 
currently the major causes of disease-related 
deaths in SSc, while scleroderma renal crisis 
was the predominant cause of death in previous 
decades.1 6 7 Skin, gastrointestinal (GI) and 
musculoskeletal involvement, digital ulcers 
(DU) and Raynaud’s phenomenon (RP) have 
shown to be associated with high morbidity, 
reduced quality of life and lower social func-
tioning.2 3 8 9 SSc can be progressive and many 
of the disease features including ILD and GI 
dysfunction can aggravate over time.3 5 In 
2013, new classification criteria for SSc were 
launched and they have been shown to be 
a major step forward in identifying patients 
with SSc particularly at early stages compared 
with previous criteria.10 11 Although early clas-
sification has been improved, there are no 
standardised international guidelines for the 
follow-up of patients with SSc. One exception 
is the 2015 European Society of Cardiology 
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and the European Respiratory Society (ESC/ERS) guide-
line recommending annual echocardiography (echo) 
in all patients with SSc to determine the risk of pulmo-
nary hypertension (PH).12 13 Recent studies indicate that 
echo screening has resulted in earlier PH diagnosis, with 
earlier onset of specific therapies and increased survival.14 
It is therefore conceivable that a standardised follow-up 
of other disease features than PAH could have benefi-
cial effects on morbidity and mortality in patients with 
SSc, improve quality of care and impact quality of life. 
The follow-up of patients with SSc may also vary between 
academic centres and non-academic centres; therefore, 
a unified, standardised annual systemic assessment of 
organ involvement in SSc should exist to guarantee all 
patients with SSc an adequate standard of care regardless 
of location and centre.13 15
The European Scleroderma Trials and Research group 
(EUSTAR) has been founded in Europe to foster the study 
of SSc with the aim of achieving equality of assessment 
and care of patients with SSc according to evidence-based 
principles throughout the world.16–18 Their work has 
enhanced the awareness of SSc worldwide substantially 
leading, among other things, to an increased number of 
clinical trials.19 20 With new treatment options for SSc in 
pipeline, the interest in developing valid methods for a 
standardised follow-up of patients has increased to diag-
nose disease progression at an early stage and to be able 
to start treatment in a timely matter.19
The aim of the present study was to establish an expert 
consensus regarding the annual systemic assessment of 
organ involvement in SSc and to develop easily appli-
cable tools that may ensure an adequate standard of care 
for all patients with SSc and enhance the standardisation 
and homogenisation of the practices worldwide.
MaTeRIal and MeTHods
Initiation, steering board and participating centres
This study was initiated by the EUSTAR board and led by 
the first and last author (AMHV and YA). The steering 
board of the study included the EUSTAR board (YA, OD, 
OK), the first author (AMHV), the president of the Scle-
roderma Clinical Trial Consortium (SCTC) (MB) and an 
invited international SSc expert from Northern America 
(DK). All experts in SSc registered in the EUSTAR network 
and the SCTC were invited to participate in the study to 
cover a broad spectre of physicians following patients 
with SSc. All participants were individually informed and 
invited multiple times by email in December 2016. The 
final independent expert panel included a multidisci-
plinary team including rheumatologists, dermatologists, 
pulmonologists, cardiologists and nephrologists. No 
patients were represented in the process.
delphi method
The Delphi method is a systematic interactive way of 
gaining opinions from a panel of independent experts 
over two or more steps frequently applied in medical and 
health service research. It is a type of consensus method 
which does not require face to face meetings and thereby 
enables participation of experts without geographic limi-
tations; and the internet-based method allows a large 
number of experts to participate worldwide. Through 
the stepwise procedure, participants can change their 
opinion after statistical feedback of the group response 
in consecutive stages of the process. The Delphi method 
was internet-based and completed from December 2016 
until October 2017. To ensure security and confidenti-
ality, each participant received a web link attached to 
the email invitation, allowing individual access to the 
questionnaire. All participants received three email 
reminders per step. It was possible to interrupt the survey 
at any time and complete it later. The survey was pilot 
tested by the initiators.
delphi rating
The goal of the different steps was to reduce the range of 
responses and arrive ultimately at an expert consensus. 
The method included five Delphi steps and entailed the 
entire group of experts who anonymously replied to in 
total five online questionnaires (figure 1) and a last step 
including solely the steering committee. The participants 
did not have the ability to see comments or answers from 
other participants. Every item in every questionnaire and 
step was asked to be rated between 0% and 100%, with 
100% as ‘very important/appropriate’ and 0% as ‘not 
important/appropriate at all’. Participants did not have 
to provide a ranking of each individual domain and/or 
tool to be able to finish the survey in any step. Consensus 
was defined based on ratings of the experts. In all steps, 
parameters rated >80% by more than 75% of the experts 
were regarded as consented.21 Parameters regarded as 
consented were reconciled by the study initiators before 
proceeding to the next step. All experts subsequently 
received feedback in the form of a statistical representa-
tion of the ‘group response’ per email after each step 
before the process repeated itself.
First step
In the first step, domains of interest for an annual system-
atic investigation were determined. All experts were 
contacted by email and asked to provide an overview over 
their proposed domains to establish a consensus agree-
ment for annual systemic assessment of patients with SSc 
(figure 1).
second step
In the second step of the Delphi survey, participants were 
asked to rate every single domain included based on 
the information received by the experts in the first step 
(figure 1). All experts received a web link sent by email 
and were asked to answer the question: ‘Which domains 
do you strongly suggest for the minimum annual systemic 
investigation of SSc patients’; and to score each individual 
item included in the survey as mentioned above. This step 
in the Delphi survey was performed to give responders 
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Figure 1 Delphi method applied to achieve expert consensus on standardised assessment of organ involvement in SSc. SSc, 
systemic sclerosis.
the chance to reflect their opinion on specific items of 
the previous step.
Third step
In the third step, proposed tools for each domains of 
interest for an annual systematic investigation were deter-
mined. All experts were contacted again by email and 
asked to provide an overview over their proposed tools 
for each domain to establish a consensus agreement for 
annual systemic assessment of patients with SSc similar to 
step 1 (figure 1). All participants were at the same time 
informed about the results from the second Delphi step.
Fourth step
In the fourth step of the Delphi survey, participants 
were asked to rate the tools for each domain based on 
the received information from the experts of step 3 
(figure 1). In this step, all experts received web links 
sent by email and were asked to answer the question for 
each tool: ‘Which tools for each domain do you strongly 
suggest for the minimum annual systemic investigation of 
SSc patients’; and to score each individual item included 
in the survey as mentioned above. To reduce the lengths 
of the questionnaires, the 10 domains were separated 
into five links, sending out with a web link once a week.
Fifth step
The preliminary results from the fourth step were shown 
and discussed with the experts at the EUSTAR reloaded 
meeting in Florence in August 2017 where all EUSTAR 
centres were invited to participate. This was followed by 
the fifth step in the Delphi survey, where all participants 
received a web link sent by email to answer the question 
for each domain: ‘Which final tools for each domain do 
you strongly suggest for the minimum annual systemic 
investigation of SSc patients’ and to score each individual 
item included in the survey. This step was performed to 
repeat the rating of all included domains and tools from 
the previous steps to reflect their opinion for a last time 
on specific tools for each domain.
last step
In a last step, the steering board perused all final 
tools (box 1) for feasibility reasons, faces validity and 
phrasing and discussed every single variable in multiple 
rounds.
statistics
Analyses were performed with IBM SPSS software, V.22, 
and STATA software, V.14. Descriptive statistics were 
applied.
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box 1 overview of the tools for each domain that the 
ssc expert panel agreed on for the longitudinal annual 
assessment of organ involvement in systemic sclerosis
1. domain: Raynaud’s phenomenon
Symptoms: Frequency and severity of attacks
2. domain: skin and mucosa
Symptoms: Skin changes (worsening or improvement; patient 
reported)
Clinical assessment: Puffy fingers, modified rodnan Skin Score 
(mrSS), telangiectasias, calcinosis
3. domain: Musculoskeletal
Symptoms: Muscle weakness and stiffness
Clinical assessment: Puffy fingers, joint contractures, arthritis, 
calcinosis, tendon friction rub count
4. domain: digital ulcers
Symptoms: Fingertip ulcers, finger ulcers proximal of DiP joints, 
development of new ulcers during the last year, coexisting conditions 
relevant for perfusion (ie, diabetes), smoking status
5. domain: lung
Symptoms: Dyspnoea
Functional assessment: Functional class (nYHa 1–4)
Clinical assessment: Basal lung crackles on auscultation
Investigation: lung function test and DlcO
6. domain: Heart
Symptoms: Dyspnoea
Functional assessment: Functional class (nYHa 1–4),
Clinical assessment: leg oedema
Investigation: ecg, Doppler-echocardiography, heart rate, blood 
pressure
Others: concurrent heart disease
7. domain: Gastrointestinal
Symptoms: night and day time heart burn/reflux, dysphagia, 
diarrhoea, weight loss
Clinical assessment: Weight
8. domain: Renal
Investigation: Serum creatinine, egFr, urine analysis, blood pressure
9. domain: laboratory
Investigation: acute phase reactants, creatine kinases, haematology, 
renal function test, liver function test
10. domain: Treatment
type of treatment (generic and name of drug), date of initiation, date 
of finalisation of every medication
ecg, electrocardiography; gi, gastrointestinal; nYHa, new York Heart 
association.
ResulTs
Response rate and characterisation of the participating 
centres
Of the 269 invited registered experts from EUSTAR and/
or SCTC, 157 (58.4%) participated in at least one of the 
steps in the Delphi survey. In 46 cases (17.1%), the emails 
were not able to deliver due to unknown recipients. In 
step 1, 132 (84.1%) participants responded. Step 2 was 
answered by 118 participants (75.2%), step 3 by 125 
(79.6%), step 4 by 108–115 (68.8%–84.1%) and step 5 
by 126 (80.3%), respectively. Of the participants, 71.3% 
were seeing >50 patients with SSc annually and 48.3% 
seeing >100 patients on an annual basis. Of all, 115 of 
the centres of the participating experts were located in 
Europe (73.2%), 23 in North America (14.6%), 9 in Asia 
(5.7%), 6 in South America (3.8%) and 4 in Oceania 
(2.5%).
domains and tools determined through five delphi steps
In the first Delphi step, 23 domains were suggested by 
the expert participants and sent individually to the study 
lead. In the second step, these domains were rated by 
the experts as shown in figure 2. Out of the 23 domains, 
10 domains were rated as >80% by>75% of all partic-
ipating experts. Nine were included in the fourth step 
by the definition of reached consensus. The ‘Raynaud’s 
phenomenon and digital ulcer’ domain was excluded by 
the study lead since it fully equalled to the single domains 
for ‘Raynaud’s phenomenon’ and ‘digital ulcer’. The 
musculoskeletal domain was rated as 74.2% by >80% of 
the experts and did not meet the a priori definition for 
consensus. It was nevertheless included as a domain after 
discussion of the study lead due to the borderline rating 
and the importance of this domain for measuring disease 
activity in SSc. All participants were informed about the 
decision and the rationales before starting in step 3. No 
complaints from the participants were received.
In the third round, a large number of tools for each 
domain were sent from each individual participant to 
the study lead (online supplementary table 1). All the 
received tools were included in the online survey of the 
fourth step and rated by all participating experts. The 
tools for each of the 10 domains that were rated as >80% 
by >75% by all experts were included in the last step of 
the Delphi survey (online supplementary table 1). These 
results were presented and discussed at the EUSTAR 
meeting with 70 participating experts. Rationales for 
including the musculoskeletal domain were once more 
presented and broad approval achieved by the partici-
pating experts.
In the last Delphi round, all tools for each domain 
from the fourth round were re-rated. Another 11 tools 
from step 4 were excluded and the final tools for each 
domain are shown in box 1.
last step
In a last step, the steering board perused and discussed 
all final tools for clarification of the terminology, but did 
not remove any items. The final consensus was consid-
ered as having high face validity with regard of the trans-
parency and relevance of included items.
A case report form was developed by the steering board 
(online supplementary table 2) for practical implications 
that can easily be applied if preferred by the physicians 
following patients with SSc longitudinally. Since the 
consensus does not contain specified measures for the 
included items, for all tools overlapping with items from 
the existing EUSTAR registration, their measures and 
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Figure 2 Results from the second Delphi step showing the percentage of rated domains that the experts agreed on as 
domains for the annual systemic assessment of organ involvement in systemic sclerosis. DU, digital ulcers; GI, gastrointestinal; 
RP, Raynaud’s phenomenon.
definitions were chosen due to long experience and use 
of the majority of participating experts. As this step was 
no longer part of the consensus, this is the sole opinion 
of the steering board rather than a consensus of the 
whole group.
dIsCussIon
Achieving equality of assessment worldwide will most 
likely increase the standard of care for SSc. However, to 
date there are no existing guidelines for standardised 
follow-up of patients with SSc. In this study, we developed 
an expert consensus on the requirements for annual 
assessment of organ involvement in SSc by applying the 
Delphi method. We propose a minimum set of 10 key 
domains in SSc with related sign/symptoms and tools 
for assessment. All the items are easily applicable, even 
in non-academic centres, and we believe that they ensure 
an adequate standard of care for patients with SSc world-
wide.
There are few existing expert consensus and sugges-
tions from single centres or national networks on SSc 
follow-up, mainly focusing on one single organ, but to 
the best of our knowledge, this is the first study where an 
international multidisciplinary panel reached consensus 
on the longitudinal follow-up scheme covering all core 
clinical domains in SSc.13 22
To reach consensus, we applied the Delphi method 
including a structured flow of information, with 
repetition and feedback and anonymity for the partici-
pants during the exercise. Aiming to develop tools that 
should be applicable in most clinical practices and easy 
to implement across health systems and national regu-
lations, we considered it as important to design a broad, 
multidisciplinary panel including five different disci-
plines that would cover a wide range of experience with 
patients with SSc (from academic centre experts, clini-
cians from non-expert centres to researchers with little 
clinical experience) and the most important specialities 
involved in the care of patients with SSc (rheumatology, 
dermatology, cardiology, pulmonology and nephrology). 
We chose an ambitious inclusion of participants and 
invited all members of EUSTAR and SCTC to cover 
afore-mentioned demands and achieved to include a 
large amount of experts. The response rate was compa-
rable to previously published Delphi exercises, but some-
what lower than anticipated, probably due to the fact that 
not all participants could be addressed personally due to 
limitations of updating email addresses of international 
experts registered in EUSTAR and SCTC.13 However, the 
total number of participating experts in this Delphi and 
the response rate to the different steps throughout the 
process was constant and high.
In 2011, Khanna et al performed a comprehensive 
literature review and the RAND/UCLA appropriateness 
method and proposed a set of quality indicators (QIs).23 
In total, six domains were included in the follow-up 
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section. Interestingly, by comparing the 10 items included 
in the tools in the present study, we found partly over-
lapping results except for the musculoskeletal domain 
where the QI included more comprehensive assessments 
taking into account MRI and EMG.23 Conversely, in the 
present study, the domains ‘DU’, ‘RP’ and ‘skin and 
mucosa’ were included as well as more tools in the labo-
ratory domain. The domains of this study additionally 
overlap to a large degree with the domains in the treat-
ment guidelines for SSc strengthening the importance of 
the core clinical domains in the final consensus.24 For the 
musculoskeletal domain, we made an exception of the 
entry criteria due to the importance of this domain for 
measuring disease activity in SSc. This might be a point of 
discussion; however, the participants were informed and 
in the next step and at the EUSTAR meeting, and there 
was no disagreement.
The information collected should have ideally reflected 
disease activity, disease status (remission) and organ 
damage, to predict outcomes and modulate treatment 
regimen. Unfortunately, in patients with SSc, concept of 
remission/low disease activity has never been validated 
and was therefore not considered in this consensus.
It must be emphasised that the final domains and 
assessment tools of this Delphi survey are the subjec-
tive opinion of experts in the field. This should not be 
confused with validation of particular domains and 
measurement tools, which was not the aim of the present 
study. Also, local feasibility, the applicability and useful-
ness of the present consensus data need to be evaluated 
in the respective countries due to varying possibilities in 
the different health systems. Hence, it will be necessary 
to formally validate the present expert consensus data 
in future studies and to conduct systematic literature 
reviews on the single domains and tools. Additionally, 
these consensus data should be evaluated by represen-
tatives of patients with SSc with distinct pathologies to 
add their opinions on priorities, effectiveness and mean-
ingfulness of the consensus data, for weighing risks and 
benefits and assessing acceptability and feasibility.25
There are a number of other limitations to this study. 
Consensus statements are, in general, graded as the 
weakest form of evidence. However, they are still consid-
ered as the optimal method for identifying areas of interest 
for further research and future practice. The selection 
of experts is another critical issue with consensus state-
ments. The group of experts involved in this study were 
all members of EUSTAR or SCTC with varying expertise 
and some experts might have been missed. Since SSc is 
a clinically heterogeneous disease, items required for 
assessment may also be different among patients: that 
is, dcSSc vs lcSSc, and early dcSSc and late dcSSc. This 
may influence items required for assessment and an 
interval of assessment but has not been considered in this 
consensus.
In conclusion, through five Delphi rounds with 
world leading experts in SSc, an expert consensus was 
established on strongly suggested tools for a minimum 
annual systemic assessment of organ involvement in SSc.
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